AAM: Generic medicines increase patient access more than government negotiated price controlsAAM is urging Congress and regulators to stop patent abuses and streamline approvals. Sandoz report weighs in on how to solve America’s drug shortage problem For the last six years, 84% of the medicines in shortage have been generics. FDA gives Lupin approval for bumetanide injection Bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic disease and renal disease. Biosimilars Council urges House to pass patent thicket legislation S. 150 passed the Senate and was placed on the House of Representatives' suspension calendar. Do consumers prefer to purchase medicines online or in-store? A significant share of respondents prefer buying medicines in person, per a YouGov survey. FDA approves Roche’s Ocrevus Zunovo with Halozyme’s Enhanze drug delivery technology Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. Alembic intros acitretin capsules Acitretin capsules are indicated for the treatment of severe psoriasis in adults. Alembic intros fluphenazine hydrochloride tablets Fluphenazine hydrochloride tablets are are indicated in the management of manifestations of psychotic disorders. iA and Parkland Health complete centralized pharmacy fulfillment project The iA partnership allows Parkland Health to manage the inventory and fulfillment process from prescription acceptance to delivery. AAM, Biosimilars Council releases statement on statement on Senate Judiciary Markup of PREVAIL and PERA The Association for Accessible Medicines and its Biosimilars Council oppose passage of the PREVAIL Act and the PERA Act. First Previous 15 16 17 18 19 Next Last
